Duloxetine Delayed-Release Capsules Nationwide Recall for N-Nitroso Impurity
Rising Pharma recalls Duloxetine Delayed-Release Capsules 20 mg nationwide due to N-nitroso-duloxetine impurity exceeding recommended interim limits, affecting 209,376 bottles.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a recognized hazardous impurity (N-nitroso compounds) detected above regulatory limits, fitting the criterion 'risk-of-harm products where injury has not yet been reported.' Though no illnesses or injuries are currently reported, N-nitroso impurities are documented manufacturing concerns warranting the High severity level.
Plain-English summary
Duloxetine Delayed-Release Capsules USP, 20 mg, are being recalled nationwide by Rising Pharma Holdings, Inc., because of the presence of N-nitroso-duloxetine impurity above recommended interim limits. The recall covers approximately 209,376 bottles distributed across the United States.
The impurity was identified through Current Good Manufacturing Practice (CGMP) compliance monitoring. To date, no patient illnesses or injuries have been reported in connection with this recall.
The affected lots include: DT2022023A, DT2022024A, DT2022025A, DT2022026A, and DT2022027A (expiring November 2024); and DT2023001B, DT2023004A, DT2023005A, and DT2023006A (expiring January 2025). The product is Rx-only and distributed by Rising Pharma Holdings, Inc., of East Brunswick, New Jersey.
The recalled product
- Product
- Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60
- Manufacturer
- Rising Pharma Holding, Inc.
- Category
- Drug
- Affected units
- 209,376
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- a) Lot # DT2022023A
- DT2022024A
- DT2022025A
- DT2022026A
- DT2022027A
- exp. date Nov-24 DT2023001B
- DT2023004A
- DT2023005A
- DT2023006A
- exp. date Jan-25
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Rising Pharma Holding, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Rising Pharma Holding, Inc.
See all →- ModerateCyproheptadine Hydrochloride Syrup Recall Due to Precipitate
FDA (Drugs) · 2026-07-29
- HighTemozolomide capsules recalled after failing impurities and degradation specifications
FDA (Drugs) · 2026-03-11
- HighParkinson's tablets recalled after bottles contained a higher strength tablet
FDA (Drugs) · 2025-10-22
- HighDuloxetine Delayed-Release Capsules Recalled for N-Nitroso Impurity Above Safe Levels
FDA (Drugs) · 2025-03-26
- HighDuloxetine Delayed-Release Capsules recalled for manufacturing deviation and impurity
FDA (Drugs) · 2025-01-15
Same hazard · n nitroso impurity
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11